Navigation Links
InterMune Reports Second Quarter 2014 Financial Results and Business Highlights
Date:8/6/2014

rst six months of 2014 was $124.8 million, or $1.32 per share, compared with a net loss of $112.7 million, or $1.42 per share, in the comparable six months of 2013.As of June 30, 2014, InterMune had cash, cash equivalents and available-for-sale securities of approximately $560.2 million.Guidance for 2014 Revenue and Operating Expenses The company updated its forward-looking financial guidance for Esbriet revenue and operating expenses in 2014, from that provided on May 1, 2014.

Esbriet revenue: The company currently expects 2014 revenue to be toward the upper end of the increased projection of $130 to $140 million that InterMune provided in May 2014.  With regard to its 2014 revenue guidance, InterMune noted the following:

  • The typical decrease in doctor visits by patients and sales forces in Europe during the third quarter due to the summer holidays is expected.
  • The company anticipates the impact on Esbriet revenue in Europe due to the ASCEND results presented in May will not be meaningful until 2015 when the European prescribing information (SmPC) is amended to reflect the ASCEND data, which is expected to occur in early 2015.
  • InterMune has not achieved reimbursement for Esbriet in Canada from any of the public payers (provincial and territorial) and the company currently does not expect public reimbursement to begin there until 2015.
  • InterMune is not providing forward-looking guidance for potential pirfenidone revenue in the United States in 2014.  If the pirfenidone NDA is approved in 2014, the company would expect to recognize only very modest revenues from sales of Esbriet in the United States in 2014 given that: the PDUFA date is November 23, 2014, which is immediately prior to the November and December holiday periods and will decrease patient-doctor appointments; InterMune's closed, direct distribution system will be managed by a relatively small number of specialty pharmacy distributors who tradit
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related medicine technology :

    1. The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
    2. InterMune Announces Proposed Public Offering of Common Stock
    3. InterMune Reports Second Quarter 2013 Financial Results And Business Highlights
    4. Sean P. Nolan Joins InterMune as Executive Vice President and Chief Business Officer
    5. InterMune Announces Presentations of New Research in IPF at ERS
    6. InterMune Reports Second Quarter 2012 Financial Results and Business Highlights
    7. InterMune to Divest Actimmune® (Interferon Gamma-1b)
    8. Neurocrine Biosciences Reports Second Quarter 2014 Results
    9. Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2015
    10. China Biologic Reports Financial Results for the Second Quarter of 2014
    11. Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/15/2014)... , December 15, 2014 Investor-Edge has ... ZGNX ), Eli Lilly and Company (NYSE: ... (NYSE: SNY ), and Novartis AG (NYSE: ... be accessed at: http://investor-edge.com/register . On Friday, ... 1.16%, the Dow Jones Industrial Average lost 1.79%, to finish ...
    (Date:12/15/2014)... and BOSTON , December 15, 2014 ... structure-guided drug discovery and development company, is pleased to ... the United States relating to its ... in the US significantly strengthens the global patent estate ... markets. The suite of patents recently granted ...
    (Date:12/13/2014)... HUNTSVILLE, Ala. , Dec. 12, 2014 /PRNewswire-USNewswire/ ... has purchased the HiSeq X Ten sequencing system ... will enable HudsonAlpha to produce and analyze genomic ... purchase stems from the Institute,s commitment to research ... The HiSeq X Ten provides unprecedented capacity, ...
    Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
    ... InterMune, Inc. (Nasdaq: ITMN ) today ... development program for pirfenidone and idiopathic pulmonary fibrosis (IPF) ... European Respiratory Society (ERS), to be held September 18-22 ... Executive Officer and President of InterMune, said, "We are ...
    ... Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin ... announced today that its President and Chief Executive Officer ... highlighting recent developments at the Rodman & Renshaw 12th ... will take place on Wednesday, September 15, 2010 at ...
    Cached Medicine Technology:InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 2InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 3InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 4InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS) 5Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT 2Soligenix to Present at the Rodman & Renshaw Healthcare Conference on September 15, 2010 at 10AM EDT 3
    (Date:12/17/2014)... Dr. Myo Nwe is the co-author of a new ... and co-founder of the Ace Medical Weight Loss Center in ... broad look at the industry of weight loss, and how ... film and in television shows, however, she says the topic ... and played for basic laughs, which she believes impacts whether ...
    (Date:12/17/2014)... 17, 2014 This prestigious award ... that have made outstanding and innovative contributions to ... progression of private practice physical therapy by the ... Association. , On behalf of Performance Physical Therapy, ... CEO of Performance accepted the award at the ...
    (Date:12/17/2014)... (PRWEB) December 17, 2014 A group of ... for Longevity, today, in reaction to a recent statement by ... of brain training and derogated the efficacy of all brain ... agreed with the parts of the center’s statement critical of ... the center had also overstated its case, in a document ...
    (Date:12/17/2014)... (PRWEB) December 17, 2014 No matter ... been able to eradicate the head louse parasite—a common ... for parents. Each year between six and twelve million ... the Miami-based lice removal treatment company comes to the ... and environmentally friendly. With its track record of customer ...
    (Date:12/17/2014)... Project Veritas is releasing a video ... MIT economist and Obamacare architect Jonathan Gruber to public ... the interview, which is being distributed on YouTube. , ... mislabeling in the Affordable Care Act in order to ... billion dollar per year tax grab. , “President Obama ...
    Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Lice Troopers Announces New Lice Treatment Clinic in Coral Gables to Service Key Biscayne, Coconut Grove, Kendall, Brickell & South Miami 2Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2
    ... which was just approved for treating leukemia, also shows promise ... Drug Administration approved the use of a promising anti-leukemia drug ... The drug, Gleevec, administered as a pill once a day, ... its ability to target and kill cancer cells without attacking ...
    ... study on a vaccine made from the immune system ... a promising. Dr. Johannes Vieweg, associate professor of urology ... Medical Center in Durham, tested the vaccine on 13 ... uses the men's own dendritic cells, extracted white blood ...
    ... native to the South Sea Islands. It is a herb ... diseases. The herb is commonly used by consumers as a ... spasms. According to experts, the herb behaves like a class ... ,Benzodiazepines have been shown to be habit-forming when taken ...
    ... a person's face could unveil whether he or she is ... non smokers.A study by dermatologists, published in The Lancet, shows ... that breaks down collagen in the skin.// ,Collagen is ... elasticity of the skin. When this starts to deteriorate, skin ...
    ... Doctors investigating a theory that contemporary orgasms succor fertility found ... from their partners than those that did not. The best ... with your partner, scientists have ascertained. ,Dr Cathy, from ... with an average age of 32. //The women were asked ...
    ... best foot forward in completing its social responsibility. ... Zyban, its anti-smoking drug. Glaxo is aiding companies ... policy, along with providing teams to help in ... corporate, which have negotiated for this 'no-smoking' environment, ...
    Cached Medicine News:
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: